StockNews.AI
PHAT
StockNews.AI
176 days

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

1. PHAT to host Q4 and 2024 earnings call on March 6, 2025. Conference call set to update investors. 2. Live webcast available with recording for 90 days. Details on Phathom’s investor website. 3. Focus remains on novel GI treatments and exclusive rights to vonoprazan. This underpins the product pipeline.

Earnings
-1.15%Current Return
VS
-0.72%S&P 500
$5.6702/24 08:21 AM EDTEvent Start
$5.60502/25 03:02 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

Earnings release events have historically led to volatility only post-outcome. Past biotech earnings calls have shown modest immediate moves unless results differ significantly from expectations.

How important is it?

The update is critical as it could shift investor sentiment and trigger volatility. However, without disclosed results, the precise impact on PHAT remains uncertain.

Why Short Term?

Earnings announcements typically trigger market reactions in the near term. Similar events in the biotech sector have resulted in immediate price adjustments.

Related Companies

ABBVAMGN
Management to host conference call on Thursday, March 6, 2025, at 8:30 am ET FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, March 6, 2025, to report its fourth quarter and full year 2024 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting. About Phathom Pharmaceuticals, Inc.Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X. MEDIA CONTACTNick Benedetto1-877-742-8466media@phathompharma.com INVESTOR CONTACTEric Sciorilli1-877-742-8466ir@phathompharma.com © 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

Related News